tirzepatide iih Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension | The Journal of Headache and Pain What other health conditions are

In July 2025, we announced new data from Week 156 of our Phase 3 PaTHway Trial, confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism regardless of its cause (post-surgical, autoimmune, genetic, or idiopathic), including improvements in biochemistries, kidney function, and quality of life

10.1038/ncb0311-184 120 TadaY.SpoelS

Some mild reactions may improve without treatment or become less noticeable as the body adjusts

For Athletic Performance 2,000-3,000 milligrams per day Reduces fatigue, enhances endurance, and helps in faster recovery

doi: 10.1016/j.physbeh.2021.113588